Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Li, Chi-Chung
41116  Ergebnisse:
Personensuche X
?
1

Pharmacologic characterization of atogepant: A potent and s..:

Moore, Eric ; Bell, Ian M ; Fraley, Mark E...
Cephalalgia.  44 (2024)  1 - p. , 2024
Link: https://doi.org/10.1177/..
 
?
2

Mosunetuzumab monotherapy is active and tolerable in patien..:

Bartlett, Nancy L. ; Assouline, Sarit ; Giri, Pratyush...
Blood Advances.  7 (2023)  17 - p. 4926-4935 , 2023
Link: https://doi.org/10.1182/..
 
?
3

Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Eff..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S117 , 2022
Link: https://doi.org/10.1016/..
 
?
4

Poster: IBCL-249 Mosunetuzumab Monotherapy Is an Effective ..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S173 , 2022
Link: https://doi.org/10.1016/..
 
?
5

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S387 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Poster: IBCL-373: Updated Experience from Mosunetuzumab in ..:

Assouline, Sarit ; Kim, Won Seog ; Sehn, Laurie H....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S245 , 2021
Link: https://doi.org/10.1016/..
 
?
7

IBCL-373: Updated Experience from Mosunetuzumab in Multiple..:

Assouline, Sarit ; Kim, Won Seog ; Sehn, Laurie H....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S406-S407 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Mitigating the risk of cytokine release syndrome in a Phase..:

Hosseini, Iraj ; Gadkar, Kapil ; Stefanich, Eric...
npj Systems Biology and Applications.  6 (2020)  1 - p. , 2020
Link: https://doi.org/10.1038/..
 
?
9

The effect of multiple doses of ubrogepant on the pharmacok..:

Li, Chi-Chung ; Palcza, John ; Xu, Jialin...
Cephalalgia Reports.  3 (2020)  - p. 251581632090508 , 2020
Link: https://doi.org/10.1177/..
 
?
10

Single and Multiple Doses of Ubrogepant Are Not Associated ..:

Bondiskey, Phung ; Ankrom, Wendy ; Liu, Wen...
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
11

Characterization of Ubrogepant: A Potent and Selective Anta..:

Moore, Eric ; Burgey, Christopher S. ; Fraley, Mark...
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
12

Absence of Clinically Significant Drug Interactions With Co..:

Li, Chi-Chung ; Palcza, John ; Xu, Jialin...
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
13

A survey of new oncology drug approvals in the USA from 201..:

Lu, Dan ; Lu, Tong ; Stroh, Mark...
Cancer Chemotherapy and Pharmacology.  77 (2016)  3 - p. 459-476 , 2016
Link: https://doi.org/10.1007/..
 
?
14

Effect of Different Durations and Formulations of Diltiazem..:

Friedman, Evan J. ; Fraser, Iain P. ; Wang, Ying-Hong...
The Journal of Clinical Pharmacology.  51 (2011)  11 - p. 1561-1570 , 2011
Link: https://doi.org/10.1177/..
 
?
15

Discovery of MK-3207: A Highly Potent, Orally Bioavailable ..:

Bell, Ian M. ; Gallicchio, Steven N. ; Wood, Michael R....
ACS Medicinal Chemistry Letters.  1 (2010)  1 - p. 24-29 , 2010
Link: https://doi.org/10.1021/..
 
1-15